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LETTERS TO THE EDITOR
Fatal Pemetrexed-
Induced Lung Injury in
Patients with Advanced
Mesothelioma
A Report of Two Cases
To the Editor:
Pemetrexed is an antifolate chemo-
therapy agent that is active in multiple
tumor types including malignant mesothe-
lioma.1 Adverse drug reactions are mild,
and there have been no previous reports
that pemetrexed induces fatal acute lung
injury. We encountered two patients who
had been given pemetrexed and developed
a fatal lung injury.
The first case was a 71-year-old
man admitted to our hospital for evalua-
tion of chest pain and diagnosed as sarco-
matous malignant pleural mesothelioma.
The patient received chemotherapy with
cisplatin (60 mg/m2) and pemetrexed (500
mg/m2). However, 4 weeks after initiation
of the treatment, he was dyspneic. A chest
computed tomography scan demonstrated
diffuse ground-glass opacities in his right
lung (Figure 1). The patient’s white blood
cell count was 14,800/mm3, C-reactive
protein was 12.7 mg/dl, and KL-6 was
2700 U/ml (normal range: 500 U/ml).
No infectious, tumor-related, embolic, or
cardiac causes were found after extensive
workup. The patient’s clinical state deterio-
rated, andmethylprednisolone was started at
500 mg/d. Despite the treatment, his respi-
ratory status worsened, and he died 7 weeks
after initiation of the chemotherapy.
The second case was a 77-year-old
man referred to our hospital for evaluation
of dyspnea and diagnosed as biphasic-type
malignant pleural mesothelioma. The pa-
tient received chemotherapy with carbo-
platin (area under the curve  4) and
pemetrexed (500 mg/m2). Three weeks
after the start of the treatment, he pre-
sented with progressive exertional dys-
pnea. His chest computed tomography
scan demonstrated ground-glass opacities
in his left lower lobe (Figure 2). The
patient’s white blood cell count was
16,900/mm3, C-reactive protein was 9.2
mg/dl, and KL-6 was 1236 U/ml. There
were no infectious, embolic, tumor-re-
lated, or cardiac causes found after exten-
sive workup. High-dose corticosteroid
treatment was started at 500 mg/d of
methylprednisolone. However, his respi-
ratory status worsened, and he died 5
weeks after the start of chemotherapy; just
before his death, the level of KL-6 was
2417 U/ml.
There is only one published report
on pemetrexed-induced lung injury, but
that was very mild and easily treated by
corticosteroids.2 In both our cases, none of
the examinations revealed evidence of
embolic, tumor-related, cardiac, or infec-
tious causes. Moreover both patients’ se-
rum levels of KL-6 were increased re-
markably. KL-6 is a high molecular
weight, mucin-like glycoprotein classified
as human MUC1 mucin. Serum levels of
KL-6 are increased in patients with intersti-
tial lung diseases including drug-induced
pneumonitis but not in patients with bacte-
rial pneumonia or normal control subjects.3
In both patients, there were no “candidates”
that could have induced the acute interstitial
pneumonitis other than the chemotherapy
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FIGURE 1. Computed tomography scan of the chest demonstrated diffuse
ground-glass opacities in the right lung.
FIGURE 2. Computed tomography scan of the chest revealed ground-glass opaci-
ties in the left lower lobe.
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drugs; neither patient had used any new
drug other than the chemotherapy
agents. It has been reported that plati-
num rarely causes acute lung injury4; so
we, therefore, concluded that pem-
etrexed was the offender in both cases.
Several risk factors have been iden-
tified regarding gefitinib; smoking habit,
male sex, coexistence of interstitial pneu-
monia, early onset of disease, and poor
performance status.5 In both our cases,
many of these risk factors were found.
Because the role of pemetrexed in
the treatment of solid tumors continues to
expand, clinicians must be aware of this
possible severe pulmonary complication
during the management of patients with
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Compared with the more common
epithelial cancers, current knowledge
about the biology of thymic epithelial
tumors is limited. Research has been
hampered by the rarity of the tumor and
the lack of established cell lines and
animal models. Ras family plays impor-
tant roles in the regulatory processes of
proliferation, differentiation, and apo-
ptosis. A recent Caucasian report dem-
onstrated that 1 of 38 thymoma and 1 of
7 thymic carcinoma had Kras muta-
tions.1 Because we previously reported
the EGFR copy number2 and Kras muta-
tion3 status using quantitative polymerase
chain reaction (PCR) assay in non-small
cell lung cancer, we evaluated the Kras
gene mutation status and Kras gene am-
plification, which may bring important in-
formation for the surgically treated Japa-
nese thymic epithelial tumor patients.
Thymic epithelial tumor tissues
were obtained by surgical excision from
125 patients (107 thymomas and 18 thy-
mic cancers). Kras mutation status at
codon 12,13 mutation was analyzed by
quantitative real-time PCR performed us-
ing LightCycler.3 Positive sample and
some of the negative samples from melt-
ing analysis were directly sequenced. Us-
ing the LightCycler genotyping PCR as-
say, only one thymic carcinoma case was
detected to have a Kras mutation. A het-
erozygous G to T substitution at nucleo-
tide position 35 in exon 1 of Kras, result-
ing in a valine for glycine amino acid
substitution at position 12 (G12V) (Fig-
ure 1). This patient was a 38-year-old
woman with adenocarcinoma. She is a
never smoker and had stage IVb cancer
with lung metastasis. EGFR mutations
were evaluated for 105 thymomas and 11
thymic carcinomas using LightCycler
genotyping assay.4 However, no muta-
tion was found within the cohort. In lung
cancers, Krasmutation rate was lower in
Japanese when compared with Cauca-
sian.3 The difference between the previ-
ously published study1 and ours might
be caused by the difference in ethnicity:
Caucasian or Oriental. Characteristi-
cally, 70% of Kras mutations are G to T
transversions,5 molecular events that are
linked to exposure to tobacco smoke
carcinogenesis. A previous report also
showed that the mutation case from thy-
mic carcinoma was a heterozygous G to
T transversion at nucleotide position 35
in exon 1 of Kras.1 Although, in our
case, the patient was a nonsmoker, other
mechanisms such as passive tobacco
smoking might be involved.
Kras copy number was analyzed
for 13 thymic cancer and 19 advanced
thymoma patients by quantitative real-
time PCR performed on 7500 Real Time
PCR System (Applied Biosystems) by
using a QuantiTect SYBR Green Kit
(Qiagen, Inc., Valencia, CA).2 Only one
of the 13 thymic cancer case was found
to have increased Kras copy number
(3.0). This patient was a 76-year-old
man with squamous cell carcinoma. He
had stage IVb cancer with lymph node
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FIGURE 1. The data for Kras gene using direct sequencing. Left, A heterozygous G to
T substitution at nucleotide position 35 in exon 1 of Kras, resulting in a valine for gly-
cine amino acid substitution at position 12 (G12V). Right, Reverse sequencing.
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